What is the role of a coronary artery calcium (CAC) score obtained with a non‑contrast ECG‑gated CT, and how should the results guide management?

Coronary Artery Calcium Scoring: Role and Management Guide

Coronary artery calcium (CAC) scoring using non-contrast ECG-gated CT is the single most powerful tool for refining cardiovascular risk assessment in asymptomatic patients with borderline (5-7.5%) or intermediate (7.5-20%) 10-year ASCVD risk, and should guide decisions about statin therapy, aspirin use, and blood pressure management. 1

When to Order CAC Scoring

Appropriate Candidates:

• Borderline risk patients (5-7.5% 10-year ASCVD risk) where uncertainty exists about initiating statin therapy 1
• Intermediate risk patients (7.5-20% 10-year ASCVD risk) when treatment decisions are uncertain 1
• Selected younger patients (age 30-49) with multiple risk factors (smoking, hypertension, hyperlipidemia, family history of premature CAD) 1
• Patients with family history of premature CAD in the intermediate-risk category 1

Do NOT Order CAC in:

• Low-risk patients already committed to lifestyle modification only
• High-risk patients (>20% 10-year risk) already requiring statin therapy 2
• Patients with known CAD or prior revascularization
• Patients unwilling to modify therapy based on results 2

Interpreting CAC Scores and Clinical Actions

CAC = 0 ("Power of Zero"):

• Annual cardiovascular event rate <0.5% - exceptionally low risk 1
• Action: Defer statin therapy in most cases, especially without active smoking or family history of premature CAD 1
• Reassessment: Consider repeat CAC in 3-5 years depending on age and risk factor burden 1
• Exception: Active smokers and those with strong family history still warrant aggressive risk factor modification 1

CAC = 1-99 (Mild):

• Action: Favor moderate-intensity statin therapy, particularly if age >55 years 1
• Consider aspirin 81 mg daily if no bleeding contraindications 3
• Intensify lifestyle modifications

CAC = 100-399 (Moderate):

• Action: Initiate moderate-to-high intensity statin therapy 1
• Aspirin 81 mg daily is reasonable - CAC ≥100 identifies patients where aspirin benefit exceeds bleeding risk 3
• Number needed to treat (NNT) = 28-30 to prevent one ASCVD event over 10 years with statin therapy 1

CAC ≥400 (Severe):

• Action: High-intensity statin therapy mandatory 1
• Aspirin 81 mg daily unless contraindicated 3
• Consider screening for silent ischemia (Class IIb recommendation) 1
• NNT <30 for preventing cardiovascular events 1

CAC ≥1,000 (Very High):

• Represents very-high-risk phenotype requiring maximal medical therapy 4
• Consider additional risk reduction strategies beyond standard statin/aspirin

Blood Pressure Management Guidance

CAC ≥220 identifies patients with annual ASCVD risk similar to SPRINT trial participants, justifying more aggressive blood pressure targets 3. For patients with stage 1 hypertension (SBP 130-139 or DBP 80-89):

• CAC = 0: Defer pharmacologic therapy, emphasize lifestyle modification
• CAC 1-100: Consider antihypertensive therapy based on overall risk profile
• CAC >100: Initiate pharmacologic blood pressure management 3

Technical Considerations

• Radiation dose: Approximately 0.37 mSv - comparable to mammography 1
• Scan time: ~1 minute of actual scanning, 10 minutes total patient time 3
• Scoring method: Agatston score is standard; can be expressed as age/sex/race-adjusted percentile 1
• Cost: $75-250 out-of-pocket where not covered; increasingly covered by major insurers (Anthem, UnitedHealthcare, Aetna) and Medicare in some states 3

Critical Limitations and Pitfalls

CAC only detects calcified plaque - represents ~20% of total atherosclerotic burden 1. Non-calcified plaque is not visualized, meaning:

• CAC = 0 does NOT exclude obstructive CAD in symptomatic patients 1
• Young patients with acute coronary syndromes may have zero calcium
• CAC measures atherosclerotic burden, not stenosis severity 1

Incidental findings occur in 0.4-16.5% (lung nodules) requiring follow-up, potentially causing patient anxiety 1

Statin therapy increases CAC scores - serial CAC monitoring is not routinely recommended, though annual increases >15% or >100 units predict future events 1, 2

Emerging Applications

Incidental CAC on non-cardiac chest CT has similar prognostic value and represents a major untapped opportunity - approximately 20 times more chest CTs are performed annually than dedicated CAC scans 5. Semi-quantitative visual scoring on routine chest CT can guide referral for formal CAC scoring or direct treatment intensification 5, 6.

AI-automated CAC detection is increasingly feasible for both gated and non-gated CT, enabling scalable cardiovascular screening 4, 7.

Patient Counseling Requirements

Before ordering CAC, explicitly discuss:

• Results will directly influence medication decisions (statin/aspirin initiation)
• Positive findings require commitment to long-term preventive therapy
• Potential for incidental findings requiring follow-up
• Out-of-pocket cost if insurance doesn't cover 2

Only order CAC if you and the patient are prepared to act on the results - this is not a "screening test" but a decision-making tool for treatment allocation 2.